TLR7 and psoriasis: In an rIL-23-induced psoriasis mouse model, a TLR-7,−8, and−9 antagonist inhibited the dermal expression of Nlrp3 and Aim2 and reduced the secretion of Th1 and Th17 cytokines in skin and serum, suggesting that inflammasomes might be a therapeutic target for psoriasis treatment (106).